menu
    • menu
    [{"orgOrder":0,"company":"Synlogic","sponsor":"Ginkgo Bioworks","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"SYNB2081","moa":"","graph1":"Rheumatology","graph2":"IND Enabling","graph3":"Synlogic","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"","sponsorNew":"Synlogic \/ Ginkgo Bioworks","highestDevelopmentStatusID":"5","companyTruncated":"Synlogic \/ Ginkgo Bioworks"},{"orgOrder":0,"company":"Jiangsu Atom Bioscience & Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"ABP-745","moa":"","graph1":"Rheumatology","graph2":"IND Enabling","graph3":"Jiangsu Atom Bioscience & Pharmaceutical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"","sponsorNew":"Jiangsu Atom Bioscience & Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Jiangsu Atom Bioscience & Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"PK MED","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Colchicine","moa":"","graph1":"Rheumatology","graph2":"IND Enabling","graph3":"PK MED","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Injection, Prolonged Release","sponsorNew":"PK MED \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"PK MED \/ Not Applicable"},{"orgOrder":0,"company":"Monte Rosa Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"MRT-8102","moa":"","graph1":"Rheumatology","graph2":"IND Enabling","graph3":"Monte Rosa Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"","sponsorNew":"Monte Rosa Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Monte Rosa Therapeutics \/ Not Applicable"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Monte Rosa Therapeutics

                            U.S.A arrow
                            Pharma Manufacturing 2024
                            Not Confirmed

                            Monte Rosa Therapeutics

                            U.S.A arrow
                            Pharma Manufacturing 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MRT-8102

                            Therapeutic Area : Rheumatology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Monte Rosa Begins IND Studies for MRT-8102, a NEK7 Directed Degrader

                            Details : MRT-8102 is a first-in-class NEK7-directed molecular glue degrader and NLRP3/IL-1β pathway inhibitor being evaluated for multiple inflammatory diseases, including gout and pericarditis.

                            Brand Name : MRT-8102

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 11, 2024

                            Lead Product(s) : MRT-8102

                            Therapeutic Area : Rheumatology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            PK MED

                            France arrow
                            Pharma Manufacturing 2024
                            Not Confirmed

                            PK MED

                            France arrow
                            Pharma Manufacturing 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Colchicine,Ropivacaine Hydrochloride

                            Therapeutic Area : Rheumatology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            PK MED Gets FDA Clearance to Initiate Clinical Program for PKM-01 in Gout Flares

                            Details : PKM-01 (colchicine) is an intra-articular combination of a fast-acting anesthetic and a controlled-release form of a powerful anti-inflammatory agent (colchicine). Being evaluated for gout flares.

                            Brand Name : PKM-01

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 26, 2024

                            Lead Product(s) : Colchicine,Ropivacaine Hydrochloride

                            Therapeutic Area : Rheumatology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Jiangsu Atom Bioscience & Pharmaceutical

                            China arrow
                            Pharma Manufacturing 2024
                            Not Confirmed

                            Jiangsu Atom Bioscience & Pharmaceutical

                            China arrow
                            Pharma Manufacturing 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ABP-745

                            Therapeutic Area : Rheumatology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Atom Bioscience Receives FDA IND Clearance for Clinical Trial of ABP-745 for Acute Gout

                            Details : ABP-745 is an oral small molecule for treating acute gout, showing significant safety improvement and reducing inflammatory factors in preclinical trials compared to similar drugs.

                            Brand Name : ABP-745

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 02, 2024

                            Lead Product(s) : ABP-745

                            Therapeutic Area : Rheumatology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Synlogic

                            U.S.A arrow
                            Pharma Manufacturing 2024
                            Not Confirmed

                            Synlogic

                            U.S.A arrow
                            Pharma Manufacturing 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SYNB2081

                            Therapeutic Area : Rheumatology

                            Study Phase : IND Enabling

                            Sponsor : Ginkgo Bioworks

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Synlogic Announces Synthetic Biotic for Gout Developed in Partnership with Ginkgo Bioworks

                            Details : The new candidate, SYNB2081, is a Synthetic Biotic and is the second product to advance to clinical development through a research collaboration between Synlogic and Ginkgo, following investigational new drug candidate SYNB1353 for the potential treatmen...

                            Brand Name : SYNB2081

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            August 11, 2022

                            Lead Product(s) : SYNB2081

                            Therapeutic Area : Rheumatology

                            Highest Development Status : IND Enabling

                            Sponsor : Ginkgo Bioworks

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth